JPMorgan Global Select Equity ETF (JGLO) made 10 position additions and 7 reductions on Thursday, with gross activity of $122.6 million against $6.19 billion in assets. The fund was a net seller of $33.0 million, as sales of Alphabet ($22.0 million) and Apple ($21.0 million) outweighed its largest purchase, Microsoft ($18.9 million). Other notable buys included NXP Semiconductors ($6.6 million) and Meta Platforms ($6.4 million), while Taiwan Semiconductor ($16.2 million) was among the trimmed holdings. No positions were newly opened or fully exited.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
ETFMSFTsemiconductorscapital flows
Open a keyword to see other news on the same topic.
Related tickers and likely impact
MSFT
• NeutralMicrosoft
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Systems Software |
| Market cap | $3.9T |
| Close on 10/30/2026 | 521.90 |
| Change that session | -1.55% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- What iShares Russell 1000 Value ETF (IWD) Bought: Apple Leads on Thursday
iShares Russell 1000 Value ETF (IWD) was the only ETF buying on Thursday, with no ETFs selling, recording $140.6 million in gross trades that were all net buying. The fund increased 849 positions and decreased none, with assets under management of $83.22 billion. Its largest purchases were Apple ($8.7 million), Amazon.com ($8.1 million) and Microsoft ($7.4 million), followed by Berkshire Hathaway Class B ($3.8 million) and JPMorgan Chase ($3.5 million). None of the largest buys were new positions, and there were no sellouts.
- Applied Materials (AMAT) Sees $77.8 Million in Net ETF Selling on Oct. 29
On Thursday, 45 ETFs bought Applied Materials (AMAT) shares versus 28 selling, but the sellers moved larger amounts, producing $77.8 million in net ETF selling and ending a four-day stretch of net buying. The largest sellers were QQQ ($33.2 million), TECL ($19.2 million) and SPY ($10.3 million), with QQQ cutting 78,656 shares, a 0.47% decline in its stake at a 1.45% weight. Over the last five reported days, ETFs were net buyers on four and net sellers on one. Applied Materials, a leader in materials engineering solutions used to produce virtually every semiconductor, has a $309.6 billion market cap and reported $30.84 billion in trailing-12-month revenue, up 9.9%. The stock has a GF Score of 92, trades at $390.09 above its $260.67 GF Value, and is up 52.33% year to date.
- ETFs Are Net Sellers of Broadcom (AVGO) on Thursday
ETFs were net sellers of $164.2 million of Broadcom (AVGO) on Thursday, although 46 funds bought and 29 sold, with the buying amounts smaller. QQQ led the selling, cutting 170,752 shares for a $58.9 million reduction, followed by SPY ($50.3 million) and TECL ($46.5 million). The outflow ended a four-day run of net buying, which included $169.2 million on Oct. 28 and $122.3 million on Oct. 23. Over the last five reported days, ETFs were net buyers on four and net sellers on one. Broadcom, a semiconductor and infrastructure software company, has a market cap of $1.56 trillion; its trailing-12-month revenue was $89.10 billion, up 47.3% over one year, and its year-to-date return is -5.27%.
- ETFs Are Net Sellers of Micron Technology (MU) on Oct. 29
ETFs were net sellers of $175.9 million of Micron Technology (MU) on Thursday, although 52 funds bought and 26 sold, with the buying amounts smaller. Invesco QQQ Trust (QQQ) led the selling with a $104.6 million cut, followed by TECL ($39.6 million) and SPY ($32.3 million). The session came after net inflows of $215.4 million on Oct. 28 and $70.2 million on Oct. 27, and marks one day in the current selling streak. Micron is a memory and storage semiconductor company that delivers DRAM, NAND and NOR products under the Micron and Crucial brands. Its market cap is $1.00 trillion, with trailing-12-month revenue of $133.19 billion, up 250.7% over one year, and a year-to-date return of 210.22%. Over the last five reported days, ETFs were net buyers on three and net sellers on two.
- ETFs Are Net Sellers of Advanced Micro Devices (AMD) on Oct. 29
ETFs were net sellers of $181.8 million of Advanced Micro Devices (AMD) on Thursday, with 40 funds buying and 30 selling, though the buying amounts were smaller. The move followed two straight days of net buying, including $130.8 million on Wednesday and $67.7 million on Tuesday, and came after a $53.2 million net sale on Monday. QQQ led the selling with $91.6 million, followed by TECL ($47.4 million) and SPY ($28.3 million). AMD is a fabless semiconductor company that designs high-performance computing and graphics processors, with a market cap of $824.1 billion and trailing-12-month revenue of $41.30 billion, up 38.0% over the past year. Its stock is up 135.71% year to date, and over the last five reported days ETFs were net buyers on three and net sellers on two.
- Investors piled a record sum into a leveraged semiconductor ETF last week. Things didn't work out.
Traders betting bullish on chip stocks are taking heavy losses this month, as renewed fears have emerged about investment returns on the buildout of artificial intelligence.
Related markets
Latest news
- In the hunt for $1 trillion of revenue, SpaceX reportedly targets Boost Mobile for a deal
The article says there has been intense speculation about SpaceX's ambitions in the cellular market, with multiple acquisition targets suggested. Boost Mobile is the latest of these.
- Gold prices today, Monday, November 2, 2026: Gold opens at its lowest point in over a year ahead of midterms
Gold December futures opened at $3,890 per troy ounce on Monday, down 0.2% from Friday's close, and rose slightly to $3,913.70 by 7:02 a.m. ET. The opening price was the lowest since October 3, 2025, as a sharp equities selloff led investors to sell gold to raise cash, according to Dana Samuelson of American Gold Exchange. He said the gold market was already weak and vulnerable, trading just above its major July support of $3,975, and its break below that level worsened the decline. Compared with a week, a month and a year earlier, the opening price was down 3%, 7.5% and 3.7%, respectively.
- Marvell Plunges 13% on Lumentum Takeover Rumors: Make Your 3-5 Year Bet Right Now
Marvell (MRVL) shares fell 14.05% over the past week to $196.40 after reports of a possible takeover of Lumentum (LITE), and Marvell has issued no official statement. Lumentum's market cap is about $76.2 billion versus about $172.2 billion for Marvell, and the article says a deal would be a heavy lift, possibly requiring new stock or debt on top of $4.96 billion in existing debt. Marvell raised its fiscal 2027 revenue outlook to roughly $12 billion and fiscal 2028 to about $18 billion, and the stock trades at 26x forward earnings. Of 46 analysts covering the stock, 8 rate it Strong Buy, 32 Buy, 6 Hold and none Sell, with a consensus target of $340.56 implying 73.4% upside. Risks cited include reliance on a few hyperscalers and a beta of 2.26, and the fiscal third-quarter report, measured against guidance of $3.15 billion revenue and $1.10 non-GAAP EPS, is the next checkpoint.
- AWS Holds the Scale Crown, Azure Leads the Velocity Charge
AWS and Azure both posted record quarters but are growing in different ways. AWS revenue reached $45.98 billion, up 39%, its sixth straight quarter of faster growth, with a 38.7% operating margin. Azure grew 48%, daily Copilot users rose over 5x, and CFO Amy Hood forecast 49% to 50% constant-currency Azure growth next quarter. Amazon designs its own Trainium chips and plans to sell them outside AWS in late 2027, while Microsoft Cloud gross margin slipped to 66%. Microsoft generated $18.6 billion of free cash flow, while Amazon's trailing free cash outflow reached $42.4 billion.
- Tech stocks enter November after a brutal October: Is it time to buy the dip?
According to the article, both stock and bond markets are raising doubts about whether the AI trade can be sustained after a difficult October for tech stocks.
- Should You Invest $1,000 in BridgeBio Pharma Right Now?
BridgeBio Pharma (BBIO) focuses on rare genetic diseases and has two approved therapies, Attruby and Nulibry, with Attruby accounting for 71% of third-quarter revenue. The article lists three upcoming FDA milestones: a PDUFA date of Nov. 27 for BBP-418, Feb. 4 for oral infigratinib and May 8 for encaleret. Third-quarter total revenue reached $353.2 million, up 193% year over year, including $253.2 million of U.S. net product revenue for Attruby, while the EPS loss narrowed to $0.42 from $0.95. The company reported more than $1.5 billion in cash, nearly 3 times the year-ago level, after closing a $1 billion preferred equity financing. The article acknowledges risks tied to small patient populations but presents three reasons to consider the stock.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.